<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081545</url>
  </required_header>
  <id_info>
    <org_study_id>CRP19060</org_study_id>
    <nct_id>NCT04081545</nct_id>
  </id_info>
  <brief_title>Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery</brief_title>
  <official_title>The Effect of an Opioid-free Anesthetic on Post-operative Opioid Consumption After Laparoscopic Bariatric Surgery: a Prospective, Single-blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Oryhan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Mason Hospital/Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of post-operative opioid use in laparoscopic bariatric surgery patients
      receiving opioid or opioid-free anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, single-blinded, randomized controlled trial comparing
      the effect of an opioid-free general anesthetic versus a traditional anesthetic with a
      restricted quantity of opioid on postoperative opioid consumption following laparoscopic
      bariatric surgery. The study population will be composed of 196 subjects undergoing
      laparoscopic bariatric surgery at Virginia Mason Medical center randomized into two groups.
      The control group will receive a traditional opioid restrictive general anesthetic. The study
      group will receive an opioid-free anesthetic technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigators plan to enroll 196 subjects at Virginia Mason Medical Center that are undergoing laparoscopic bariatric surgery. Subjects who volunteer to be involved in the study will be randomized to either the opioid free or traditional anesthetic arm, with a computer generated arm assignment. Subjects will be blinded to the assigned arm. Group A will receive a traditional opioid restrictive general anesthetic and group B will receive an opioid-free anesthetic technique.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Total amount of opioid use within the first 24 hours after surgery in morphine equivalent doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain assessment with numeric rating scale (NRS)</measure>
    <time_frame>3 months</time_frame>
    <description>The Numeric Rating Scale (NRS) for evaluating level of pain. The rating is verbal, and the subject is asked to estimate current pain intensity on an 11-point scale, where 0 indicates no pain at all and 10 the worst imaginable pain. This will be performed in the PACU, within first 24 hours after surgery, at 30 day follow-up phone call and at 3 month follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time under general anesthesia</measure>
    <time_frame>1-5 hours</time_frame>
    <description>Time from induction to emergence of anesthesia in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with opioid-related adverse effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse effects include postoperative nausea, vomiting, pruritis, and respiratory depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return of bowel function</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to diet advancement to full liquid diet and time to first bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time to recover from general anesthesia</measure>
    <time_frame>1-3 hours</time_frame>
    <description>Time from arrival to PACU to &quot;ready for PACU discharge&quot; in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1-5 days</time_frame>
    <description>Time from PACU arrival to discharge date and time in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient satisfaction with analgesia: yes or no</measure>
    <time_frame>24 hours</time_frame>
    <description>Satisfaction with overall post-operative pain control (yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-surgical opioid prescription refills</measure>
    <time_frame>3 months</time_frame>
    <description>Number of opioid prescription refills since surgery to be assessed at 30 day follow-up phone call and 3 month follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients treated for general anesthetic adverse effects</measure>
    <time_frame>1-8 hours</time_frame>
    <description>Adverse effects include hypotension, bradycardia, nausea, vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Opioid Use, Unspecified</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Control Goup A- Opioid-based regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction
Fentanyl (50mcg IV)
Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)
Propofol 2-3mg/kg IV bolus
Rocuronium 0.6mg/kg IV bolus
Maintenance
Sevoflurane, titrated to hemodynamic stability (defined parameters)
Rocuronium intermittent boluses at discretion of anesthesiology team
May use fentanyl to treat SBP or HR &gt; 20% of baseline
Emergence
Neuromuscular reversal, dosed according to Virginia Mason protocol
May titrate in more fentanyl to a maximum dose of 200mcg throughout the case.
Patient extubated and brought to PACU
PACU opioid orders per anesthesiology team
Post-operative Nausea/Vomiting Prophylaxis
-4mg dexamethasone, 1mg haloperidol, scopolamine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group B- Opioid-free regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:
Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW
Lidocaine 1.5mg/kg IV bolus using IBW
Propofol 2-3mg/kg IV bolus
Rocuronium 0.6mg/kg IV bolus
Ketamine 0.5mg/kg IV bolus (based on IBW)
Maintenance
Sevoflurane
Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)
Lidocaine 2mg/kg/hr IV infusion using IBW
May use esmolol as needed to treat SBP or HR &gt; 20% of baseline
Rocuronium intermittent boluses at the discretion of anesthesiology team
Emergence
Dexmedetomidine infusion turned off during laparoscopic desufflation
Lidocaine infusion turned off at skin closure
Neuromuscular reversal, dosed according to VM protocol
Pt extubated and brought to PACU
PACU opioid orders per anesthesiology team
PACU orders to include one dose APAP 650mg oral solution
Post-operative Nausea/Vomiting Prophylaxis
-4mg dexamethasone, 1mg haloperidol, scopolamine patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioid Anesthetics</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>Control Goup A- Opioid-based regimen</arm_group_label>
    <other_name>Opioid-based regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non Opioid Analgesics</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>Experimental Group B- Opioid-free regimen</arm_group_label>
    <other_name>Opioid-free regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing elective laparoscopic bariatric surgery (i.e. laparoscopic
             roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy) able to provide informed
             consent

        Exclusion Criteria:

          -  Any opioid use within 4 weeks prior to surgery

          -  Chronic antiemetic use

          -  Conversion of laparoscopic to open surgery

          -  Patients unable to provide post-operative pain scores

          -  Pregnant or lactating patients

          -  Patients under 18 years of age

          -  Refusal or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Oryhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Mason Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine L Oryhan, MD</last_name>
    <phone>206-223-6980</phone>
    <email>christine.oryhan@virginiamason.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine L Oryhan, MD</last_name>
      <phone>206-223-6980</phone>
      <email>christine.oryhan@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Christine L Oryhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josiah Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett Plancich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Nguyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lily Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Hunter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohan Mallipeddi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Benaroya Research Institute</investigator_affiliation>
    <investigator_full_name>Christine Oryhan</investigator_full_name>
    <investigator_title>Anesthesiologist and Pain Medicine Physician</investigator_title>
  </responsible_party>
  <keyword>Opioid Free Anesthesia</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Non-Opioid Anesthesia</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

